Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

Reported by Yahoo Finance · Published 10 Sep 2026, 4:58 AM MYT (1 d ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

Mark Zuckerberg May Have Found Meta’s Next Hit. Would You Hand It Your Email and Passwords? 50 min ago AXTQ Is a Trading Tool, Not a Portfolio Holding. Know the Difference Before You Buy 50 min ago MNK Group completes ETU Forsikring acquisition 53 min ago Bitmine Surges 8% on Ethereum Strength After Cantor Fitzgerald Doubles Its Target, SharpLink Advances 9%, Strategy Gains 4% 55 min ago Elon Musk's tunnel company just got a fresh $3 billion injection, thanks to the United Arab Emirates 1 hr ago Stock Market Leaders Often Shine, Helped By This Sign Of Liquidity Strength 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

Summary

More in Markets

Mark Zuckerberg May Have Found Meta’s Next Hit. Would You Hand It Your Email and Passwords?

AXTQ Is a Trading Tool, Not a Portfolio Holding. Know the Difference Before You Buy

MNK Group completes ETU Forsikring acquisition

Bitmine Surges 8% on Ethereum Strength After Cantor Fitzgerald Doubles Its Target, SharpLink Advances 9%, Strategy Gains 4%

Elon Musk's tunnel company just got a fresh $3 billion injection, thanks to the United Arab Emirates

Stock Market Leaders Often Shine, Helped By This Sign Of Liquidity Strength